CRISPR cell therapy trial seeks to tame Tough-to-Treat blood cancer

NCT ID NCT05722418

Summary

This early-stage study is testing the safety and best dose of a new cell therapy called CB-011 for people with multiple myeloma that has come back or stopped responding to other treatments. The therapy uses CRISPR gene-editing technology to create 'off-the-shelf' immune cells designed to find and attack the cancer. Researchers will enroll about 50 patients to see if the treatment is safe and if it can help control the disease.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CU Anschutz Medical Campus, Anshutz Cancer Pavillion

    RECRUITING

    Aurora, Colorado, 80045, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Cleveland Clinic

    RECRUITING

    Cleveland, Ohio, 44195, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Duke University Health System (DUHS)

    RECRUITING

    Durham, North Carolina, 27705, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Froedtert and the Medical College of Wisconsin

    RECRUITING

    Milwaukee, Wisconsin, 53226, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hackensack Meridian John Theurer Cancer Center

    RECRUITING

    Hackensack, New Jersey, 07601, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Huntsman Cancer Institute, University of Utah

    RECRUITING

    Salt Lake City, Utah, 84112, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Icahn School of Medicine at Mount Sinai

    RECRUITING

    New York, New York, 10029, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Levine Cancer Institute

    RECRUITING

    Charlotte, North Carolina, 28204, United States

    Contact Email: •••••@•••••

    Contact

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Oncology Hematology Care, Inc

    RECRUITING

    Cincinnati, Ohio, 45236, United States

    Contact Email: •••••@•••••

    Contact

  • Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics

    RECRUITING

    Miami, Florida, 33136, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Tennessee Oncology

    RECRUITING

    Nashville, Tennessee, 37203, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Alabama at Birmingham

    RECRUITING

    Birmingham, Alabama, 35294, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Kentucky/ Markey Cancer Center

    RECRUITING

    Lexington, Kentucky, 40536, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Texas Southwestern Medical Center

    RECRUITING

    Dallas, Texas, 75390, United States

    Contact

    Contact Email: •••••@•••••

  • Virginia Commonwealth University

    RECRUITING

    Richmond, Virginia, 23235, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.